Your preferences have been updated successfully.
Top 30 Lists
RiverVest, Novo Ventures, Other Lead $86M Series A IN Tioma Therapeutics
The Series A financing was co-led by RiverVest Venture Partners (including 3x5 RiverVest Fund), Novo Ventures, Roche Venture Fund and S.R. One, Limited (the corporate venture capital arm of GlaxoSmithKline).
READ FULL INVESTMENT ARTICLE
In this article